- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AVE-9897 | AVE9897 | MLN3897
Compound class: Synthetic organic
Comment: MLN-3897 is a selective oral, small‐molecule receptor antagonist of CCR1  and clinical lead that was developed for immunomodulatory potential and as a chemokine signalling inhibitor to reduce multiple myeloma (MM)-related osteolytic bone disease (blocking CCL3-CCR1-mediated signalling inhibits osteoclast formation and MM cell migration and survival) . We show the chemical structure here without specified stereochemistry, as depicted in the 2016 article by Pusalkar et al. . A stereo-specified enantiomer is claimed as (abs)-50 in MIllenium Pharmaceuticals' patent US20090286823 . As there has been no formal disclosure of the name-to-structure, we show the 'flat' structure in good faith.
Analysis presented in a bioRxiv preprint (not peer reviewed) suggests that MLN-3897 impairs infection by SARS-CoV-2 in vitro .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Compound class||Synthetic organic|
|AVE-9897 | AVE9897 | MLN3897|
|GtoPdb PubChem SID||405560191|
|Search Google for chemical match using the InChIKey||ZGFJFBOLVLFLLN-ZNLRHDTNSA-N|
|Search Google for chemicals with the same backbone||ZGFJFBOLVLFLLN|
|Search UniChem for chemical match using the InChIKey||ZGFJFBOLVLFLLN-ZNLRHDTNSA-N|
|Search UniChem for chemicals with the same backbone||ZGFJFBOLVLFLLN|